Alogliptin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Alogliptin · Nesina
Marketed by Takeda Pharmaceutical Company and partners
NCT00286429 · Phase 3 · completed
The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.
Next expected readout: December 2026 · NCT07093476 (registry estimate)
Reported efficacy
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)
Result source: NCT02856113
Sitagliptin · Januvia
Marketed by Merck & Co. and partners
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)
Result source: NCT00086502
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alogliptin | Sitagliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.1%−0.6 vs placeboNCT00286429285 other results
| -0.6% vs 0.2%−0.8 vs placeboNCT000875167 other results
|
| Body weight, change (kg) | 0.6 vs 0.6±0 vs placeboNCT00286429111 other results
| -0.5 vs -1.4vs Oral SemaglutideNCT040178321 other result
|
| HbA1c below 7% | 63.3% vs 30%+33.3 vs placeboNCT012891192 other results
| 49.5% vs 36.8%+12.7 vs placeboNCT014856144 other results
|
| Fasting plasma glucose, change | -0.7 vs 0.3−1 vs placeboNCT00286429351 other results
| -0.7 vs 0.3−0.9 vs placeboNCT000875167 other results
|
| 3-point MACE (% with event) | 11.3% vs 11.8%−0.5 vs placeboNCT00968708 | —Not posted · NCT01529541 |
HbA1c, change
- Alogliptin
- -0.7% vs -0.1%−0.6 vs placeboNCT00286429
285 other results
- -0.6% vs -0.0% NCT00286455
- 0.1% vs -0.0% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.1% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.6% vs -0.1% NCT00286429
- -0.6% vs -0.0% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.6% vs -0.1% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.6% vs 0.1% NCT01023581
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -1.0% vs -1.1% NCT00395512
- -0.9% vs -0.4% NCT00432276
- -1.0% vs 0.0% NCT01263483
- -1.7% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -0.7% vs -0.6% NCT00856284
- -0.7% vs 0.3% NCT01318083
- -1.0% vs -0.2% NCT01318070
- -0.9% vs 0.0% NCT01263483
- -1.6% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.6% NCT00856284
- -0.6% vs 0.3% NCT01318083
- -0.9% vs -0.2% NCT01318070
- -0.7% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -1.0% vs -0.2% NCT00328627
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.2% vs -0.2% NCT02856113
- -0.8% vs -0.2% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- 0.1% vs 0.5% NCT02856113
- -0.8% vs -0.3% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.4% vs -0.3% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.3% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.5% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.6% vs -0.3% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.3% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.5% vs -0.1% NCT00286494
- -0.4% vs -0.1% NCT00286442
- 0.3% vs 0.8% NCT02856113
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.2% NCT00328627
- -0.7% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.3% NCT00286494
- -0.7% vs -0.1% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.5% vs -0.3% NCT00286429
- -0.4% vs -0.1% NCT00286455
- -0.4% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.4% vs -0.1% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -1.4% vs -0.2% NCT00328627
- -1.5% vs -0.2% NCT00328627
- -1.7% vs -0.2% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.7% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.2% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.4% vs -0.2% NCT00328627
- -1.4% vs -0.2% NCT00328627
- -1.6% vs -0.2% NCT00328627
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.4% vs 0.1% NCT01023581
- -1.2% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.1% vs 0.1% NCT01023581
- -1.2% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -0.7% vs 0.1% NCT01023581
- -0.8% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.6% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -1% vs -1.2% NCT00395512
- -1.0% vs -1.2% NCT00395512
- -1.0% vs -1.0% NCT00395512
- -0.8% vs -0.7% NCT00395512
- -0.6% vs -0.3% NCT00395512
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.9% vs -0.5% NCT00432276
- -0.7% vs -0.0% NCT01263483
- -0.4% vs -0.0% NCT01263483
- -0.2% vs -0.0% NCT01263483
- -1.7% vs -1.2% NCT00395512
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.8% NCT00856284
- -0.9% vs -0.4% NCT00432276
- -1.7% vs -1.2% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.8% vs -0.3% NCT00432276
- -1.6% vs -1.0% NCT00395512
- -0.8% vs -0.4% NCT00432276
- -0.6% vs -0.7% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -1.2% vs -0.7% NCT00395512
- -0.4% vs -0.4% NCT00856284
- -0.6% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.4% vs -0.1% NCT00432276
- -0.8% vs -0.0% NCT01263483
- -0.6% vs -0.3% NCT00395512
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.6% vs -0.7% NCT00856284
- -0.4% vs -0.4% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.4% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.4% vs -0.0% NCT01263483
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.2% vs -0.0% NCT01263483
- -1.5% vs -1.2% NCT00395512
- -1.4% vs -1.2% NCT00395512
- -1.3% vs -1.0% NCT00395512
- -1.0% vs -0.7% NCT00395512
- -0.5% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.5% vs -0.3% NCT00395512
- -0.3% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.6% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.7% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.4% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.2% vs -0.0% NCT00755846
- -0.5% vs 0.1% NCT01263470
- -0.7% vs 0% NCT01263470
- -0.4% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.6% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.7% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.1% vs 0% NCT01263470
- -0.5% vs 0% NCT01263470
- -0.1% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.6% vs -0.2% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.5% vs -0.2% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.9% vs -0.1% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.9% vs -0.2% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.4% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.6% vs -0.1% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.4% vs -0.4% NCT01263496
- -0.5% vs -0.4% NCT01263496
- -0.4% vs -0.2% NCT01263496
- Sitagliptin
- -0.6% vs 0.2%−0.8 vs placeboNCT00087516
7 other results
- -0.8% vs -0.1% NCT00086502
- -0.8% vs 0.2% NCT00087516
- -0.0% vs 0.2% NCT01485614
- -1.1% vs -0.7% NCT02791490
- -0.1% vs -1.0% NCT01485614
- -0.2% vs -0.7% NCT01485614
- -0.5% vs -1.1% NCT01907854
Body weight, change (kg)
- Alogliptin
- 0.6 vs 0.6±0 vs placeboNCT00286429
111 other results
- -0.2 vs 0.2 NCT00286455
- -0.7 vs -0.7 NCT00328627
- 1.1 vs 1.0 NCT00286494
- -0.7 vs -0.4 NCT00286442
- 0.7 vs -0.2 NCT00286468
- 0.5 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.5 vs -0.6 NCT00328627
- 0.9 vs 0.9 NCT00286494
- -0.6 vs -0.4 NCT00286442
- 0.6 vs -0.3 NCT00286468
- 0.3 vs 0.5 NCT00286429
- 0.1 vs -0.3 NCT00286455
- -0.6 vs -0.5 NCT00328627
- 0.6 vs 0.6 NCT00286494
- -0.6 vs -0.6 NCT00286442
- 0.4 vs -0.1 NCT00286468
- 0.2 vs 0.4 NCT00286429
- -0.0 vs -0.4 NCT00286455
- -0.5 vs -0.1 NCT00328627
- 0.4 vs 0.4 NCT00286494
- -0.5 vs -0.1 NCT00286442
- 0.3 vs -0.3 NCT00286468
- 0.7 vs 0.6 NCT00286429
- -0.1 vs 0.2 NCT00286455
- -0.0 vs -0.7 NCT00328627
- 1.5 vs 1.0 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.6 vs -0.2 NCT00286468
- 0.6 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.1 vs -0.6 NCT00328627
- 1.1 vs 0.9 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.8 vs -0.3 NCT00286468
- 0.4 vs 0.5 NCT00286429
- -0.4 vs -0.3 NCT00286455
- -0.1 vs -0.5 NCT00328627
- 0.7 vs 0.6 NCT00286494
- -0.3 vs -0.6 NCT00286442
- 0.6 vs -0.1 NCT00286468
- 0.1 vs 0.4 NCT00286429
- 0.0 vs -0.4 NCT00286455
- -0.1 vs -0.1 NCT00328627
- 0.5 vs 0.4 NCT00286494
- -0.3 vs -0.1 NCT00286442
- 0.5 vs -0.3 NCT00286468
- 1.3 vs -0.7 NCT00328627
- 2.1 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 0.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 0.4 vs -0.5 NCT00328627
- 1.0 vs -0.5 NCT00328627
- 1.1 vs -0.5 NCT00328627
- 0.2 vs -0.1 NCT00328627
- 0.7 vs -0.1 NCT00328627
- 0.9 vs -0.1 NCT00328627
- 1.3 vs -0.7 NCT00328627
- 1.9 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 1.0 vs -0.6 NCT00328627
- 1.4 vs -0.6 NCT00328627
- 1.9 vs -0.6 NCT00328627
- 0.2 vs -0.5 NCT00328627
- 0.6 vs -0.5 NCT00328627
- 0.9 vs -0.5 NCT00328627
- 0.1 vs -0.1 NCT00328627
- 0.5 vs -0.1 NCT00328627
- 0.4 vs -0.1 NCT00328627
- -0.9 vs -1.6 NCT01289119
- -0.8 vs -1.6 NCT01289119
- -0.1 vs -1.6 NCT01289119
- -0.7 vs -1.0 NCT01289119
- -0.4 vs -1.0 NCT01289119
- -0.1 vs -1.0 NCT01289119
- -0.7 vs 0.9 NCT00856284
- 0.7 vs 1.0 NCT00432276
- -0.9 vs 1.0 NCT00856284
- -0.5 vs 0.7 NCT00856284
- 0.3 vs 0.6 NCT00432276
- 1.1 vs 1.5 NCT00432276
- 0.3 vs 0.5 NCT00432276
- 0.2 vs 0.3 NCT00432276
- -0.9 vs 0.9 NCT00856284
- 1.1 vs 1.6 NCT00432276
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.6 vs 1.0 NCT00856284
- -0.5 vs 0.7 NCT00856284
- -0.6 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.8 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.3 vs 2.2 NCT00395512
- -0.5 vs 1.6 NCT00395512
- -0.8 vs 1.0 NCT00395512
- -0.3 vs 0.6 NCT00395512
- 3.1 vs 2.2 NCT00395512
- 2.4 vs 1.6 NCT00395512
- 1.4 vs 1.0 NCT00395512
- 0.8 vs 0.6 NCT00395512
- 2.5 vs 2.2 NCT00395512
- 1.9 vs 1.6 NCT00395512
- 1.2 vs 1.0 NCT00395512
- 0.7 vs 0.6 NCT00395512
- Sitagliptin
- -0.5 vs -1.4vs Oral SemaglutideNCT04017832
1 other result
- -1.8 vs -3.3 NCT01907854
HbA1c below 7%
- Alogliptin
- 63.3% vs 30%+33.3 vs placeboNCT01289119
2 other results
- 55.1% vs 30% NCT01289119
- 61.7% vs 30% NCT01289119
- Sitagliptin
- 49.5% vs 36.8%+12.7 vs placeboNCT01485614
4 other results
- 28.8% vs 16.6% NCT02791490
- 15.6% vs 5.7% NCT02791490
- 28.4% vs 33.3% NCT01485614
- 49.5% vs 77.8% NCT01485614
Fasting plasma glucose, change
- Alogliptin
- -0.7 vs 0.3−1 vs placeboNCT00286429
351 other results
- -0.9 vs 0.6 NCT00286455
- -0.3 vs 0.7 NCT01023581
- -1.0 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.5 vs 0.1 NCT00286468
- -0.6 vs 0.5 NCT00286429
- -1.0 vs 0.4 NCT00286455
- -0.5 vs 0.5 NCT01023581
- -1.3 vs 0.4 NCT00328627
- -1.2 vs -0.4 NCT00286494
- -0.9 vs -0.0 NCT00286442
- -0.8 vs -0.0 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -1.0 vs 0.3 NCT00286455
- -0.4 vs 0.6 NCT01023581
- -1.3 vs 0.1 NCT00328627
- -1.3 vs -0.5 NCT00286494
- -0.8 vs 0.1 NCT00286442
- -0.7 vs -0.4 NCT00286468
- -0.2 vs -0.1 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -0.5 vs 0.6 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.5 vs -0.3 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -1.0 vs -0.2 NCT00286468
- -0.7 vs 0.3 NCT00286429
- -1.2 vs 0.2 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.2 NCT00286494
- -1 vs -0.0 NCT00286442
- -1.2 vs -0.2 NCT00286468
- -0.6 vs 0.1 NCT00286429
- -1.0 vs 0.2 NCT00286455
- -0.4 vs 0.3 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -1.2 vs -0.1 NCT00286468
- -0.6 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.2 vs 0.3 NCT01023581
- -1.0 vs 0.1 NCT00328627
- -1.0 vs -0.1 NCT00286494
- -0.7 vs -0.0 NCT00286442
- -1.1 vs 0.0 NCT00286468
- 0.1 vs 0.3 NCT00286429
- -0.6 vs 0.6 NCT00286455
- -0.5 vs 0.7 NCT01023581
- -0.7 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.3 vs 0.1 NCT00286468
- -0.2 vs 0.5 NCT00286429
- -0.7 vs 0.4 NCT00286455
- -0.7 vs 0.5 NCT01023581
- -0.5 vs 0.4 NCT00328627
- -1.2 vs -0.4 NCT00286494
- -1 vs -0.0 NCT00286442
- -0.5 vs -0.0 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -0.9 vs 0.1 NCT00328627
- -1.0 vs -0.5 NCT00286494
- -1.0 vs 0.1 NCT00286442
- -0.5 vs -0.4 NCT00286468
- -0.3 vs -0.1 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.1 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.7 vs 0.4 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.3 vs -0.3 NCT00286494
- -1.1 vs 0.0 NCT00286442
- -1.1 vs -0.2 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.9 vs 0.2 NCT00286455
- -0.9 vs 0.4 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.3 vs -0.2 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.2 vs 0.1 NCT00286429
- -0.8 vs 0.2 NCT00286455
- -0.6 vs 0.3 NCT01023581
- -1.2 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.9 vs -0.1 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.5 vs 0.3 NCT00286455
- -0.7 vs 0.3 NCT01023581
- -0.8 vs 0.1 NCT00328627
- -0.8 vs -0.1 NCT00286494
- -0.8 vs -0.0 NCT00286442
- -0.7 vs 0.0 NCT00286468
- -2.1 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -2.2 vs 0.4 NCT00328627
- -2.4 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -2.2 vs 0.1 NCT00328627
- -2.4 vs 0.1 NCT00328627
- -3.0 vs 0.1 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -2.9 vs 0.2 NCT00328627
- -2.2 vs 0.3 NCT00328627
- -2.5 vs 0.3 NCT00328627
- -2.9 vs 0.3 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2 vs 0.2 NCT00328627
- -2.6 vs 0.2 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.4 vs 0.1 NCT00328627
- -1.8 vs 0.7 NCT01023581
- -2.5 vs 0.7 NCT01023581
- -2.3 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -1.9 vs 0.5 NCT01023581
- -2.5 vs 0.5 NCT01023581
- -2.4 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.6 vs 0.4 NCT00328627
- -2.0 vs 0.6 NCT01023581
- -2.6 vs 0.6 NCT01023581
- -2.3 vs 0.1 NCT00328627
- -2.3 vs 0.1 NCT00328627
- -2.7 vs 0.1 NCT00328627
- -1.8 vs 0.6 NCT01023581
- -2.5 vs 0.6 NCT01023581
- -2.4 vs 0.2 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -1.8 vs 0.4 NCT01023581
- -2.4 vs 0.4 NCT01023581
- -2.4 vs 0.3 NCT00328627
- -2.3 vs 0.3 NCT00328627
- -2.4 vs 0.3 NCT00328627
- -2.1 vs 0.4 NCT01023581
- -2.5 vs 0.4 NCT01023581
- -2.0 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -1.9 vs 0.3 NCT01023581
- -2.4 vs 0.3 NCT01023581
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT01023581
- -2.0 vs 0.3 NCT01023581
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.2 vs -0.3 NCT01289119
- -1.2 vs -0.3 NCT01289119
- -0.9 vs 0.7 NCT00655863
- -0.9 vs 0.3 NCT00655863
- -1.1 vs -0.2 NCT00655863
- -2.1 vs 0.7 NCT00655863
- -2.1 vs 0.3 NCT00655863
- -2.2 vs -0.2 NCT00655863
- -1.1 vs -0.3 NCT01289119
- -1.1 vs -0.4 NCT01289119
- -1.3 vs -0.4 NCT01289119
- -1.2 vs -0.4 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.3 vs -0.3 NCT01289119
- -0.9 vs -0.3 NCT01289119
- -0.7 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -0.6 vs -0.2 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.3 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.8 vs -0.3 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -1 vs -0.3 NCT00432276
- -0.5 vs -0.0 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.6 vs -0.6 NCT00856284
- -1.0 vs -0.1 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -0.9 vs -0.0 NCT00432276
- -0.4 vs 0.1 NCT00856284
- -0.8 vs -0.2 NCT00432276
- -0.3 vs 0.1 NCT00856284
- -0.3 vs 0.3 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.4 vs -0.2 NCT00856284
- -0.4 vs -0.3 NCT00856284
- -0.5 vs -0.4 NCT00856284
- -0.4 vs -0.0 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -0.5 vs -0.5 NCT00856284
- -0.6 vs -0.6 NCT00856284
- -0.6 vs -0.4 NCT00856284
- -0.3 vs 0.1 NCT00856284
- -0.2 vs 0.1 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -1.4 vs -2.1 NCT00395512
- -1.6 vs -2.3 NCT00395512
- -1.5 vs -2.3 NCT00395512
- -1.6 vs -2.4 NCT00395512
- -1.6 vs -2.1 NCT00395512
- -1.5 vs -1.8 NCT00395512
- -0.9 vs -0.8 NCT00395512
- -0.8 vs -0.4 NCT00395512
- -1.1 vs -0.3 NCT01263483
- -1.1 vs -0.1 NCT01263483
- -0.9 vs -0.0 NCT01263483
- -0.9 vs -0.2 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -3 vs -2.3 NCT00395512
- -2.9 vs -2.3 NCT00395512
- -2.9 vs -2.4 NCT00395512
- -0.9 vs 0.3 NCT01318083
- -1.1 vs -0.1 NCT01318070
- -1.0 vs -0.3 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -1.0 vs 0.3 NCT01318083
- -1.2 vs -0.2 NCT01318070
- -1.2 vs -0.1 NCT01263483
- -2.3 vs -1.8 NCT00395512
- -1.3 vs 0.1 NCT01318083
- -1.0 vs -0.2 NCT01318070
- -1.3 vs -0.0 NCT01263483
- -1.9 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -1.0 vs -0.2 NCT01263483
- -1.5 vs -0.4 NCT00395512
- -2.7 vs -2.1 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -2.7 vs -2.4 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.8 vs -0.1 NCT01318070
- -2.7 vs -2.1 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -2.2 vs -1.8 NCT00395512
- -1.2 vs 0.1 NCT01318083
- -0.8 vs -0.2 NCT01318070
- -1.7 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.7 vs -0.2 NCT01318070
- -1.3 vs -0.4 NCT00395512
- -1.5 vs 0.5 NCT00755846
- -1.0 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT01263470
- -1.4 vs 0.3 NCT00755846
- -1.1 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -0.3 vs 0.5 NCT00755846
- -0.8 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT01263470
- -0.6 vs 0.3 NCT00755846
- -1.2 vs 0.5 NCT01263470
- -0.9 vs 0.1 NCT01263470
- -1.2 vs 0.5 NCT00755846
- -1.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT00755846
- -1.3 vs 0.3 NCT01263470
- -1.3 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT00755846
- -1.3 vs 0.5 NCT01263470
- -1.2 vs 0.1 NCT01263470
- -0.4 vs 0.5 NCT00755846
- -0.5 vs 0.3 NCT01263470
- -0.7 vs 0.3 NCT01263470
- -0.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.4 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -0.9 vs -0.2 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.2 vs -0.7 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.7 vs -0.4 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.2 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -1.0 vs -0.8 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -1.1 vs -0.7 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.1 vs -0.4 NCT01263496
- -1.1 vs -0.3 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.0 vs -0.4 NCT01263496
- -1.2 vs -0.5 NCT01263496
- -1.3 vs -0.2 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.4 vs -0.7 NCT01263496
- -1.5 vs -0.5 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.5 vs -0.4 NCT01263496
- -0.6 vs -0.3 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.6 vs -0.4 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.7 vs -0.2 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.8 vs -0.7 NCT01263496
- -0.6 vs -0.5 NCT01263496
- Sitagliptin
- -0.7 vs 0.3−0.9 vs placeboNCT00087516
7 other results
- -0.9 vs 0.1 NCT00086502
- -0.9 vs 0.3 NCT00087516
- 0.4 vs 0.3 NCT01485614
- -1.6 vs -0.9 NCT02791490
- -0.5 vs -1.0 NCT04017832
- 0.6 vs -1.1 NCT01485614
- -0.2 vs -1.7 NCT01485614
3-point MACE (% with event)
- Alogliptin
- 11.3% vs 11.8%−0.5 vs placeboNCT00968708
- Sitagliptin
- —Not posted · NCT01529541
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Alogliptin: 13 of 13 rows · Sitagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alogliptin Rows use multiple source trials | Sitagliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,b,c NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted show 3 more doses-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted -0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted -0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted | -1.9 mmol/L @ 24wka,b,c NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-2.03 mmol/L @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.96 mmol/L @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| Glycemic Rescue responder rate · % of participants | 12.8% (n=125) vs 32.8% (n=125) placebo25 mga,c,d NCT00328627 · Phase 3 · registry result, not featured evidence show 7 more doses14.5% (n=124) vs 32.8% (n=125) placebo12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9% (n=129) vs 32.8% (n=125) placebo25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.9% (n=123) vs 32.8% (n=125) placebo25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.6% (n=125) vs 32.8% (n=125) placebo25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.7% (n=129) vs 32.8% (n=125) placebo12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.8% (n=126) vs 32.8% (n=125) placebo12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.4% (n=127) vs 32.8% (n=125) placebo12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination | 35.8% (n=95) vs 11.1% (n=9) Metformin @ 54wkc,d NCT01485614 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.7% (n=145) @ 24wk25 mg QD and 1-6 mg QD or BIDa,b,c NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination show 3 more doses-0.78% (n=134) @ 24wk25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination -0.59% (n=137) @ 24wk12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination -0.68% (n=135) @ 24wk12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination | -1.27% (n=183) @ 24wka,b,c NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-1.51% (n=189) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.15% (n=187) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c Decrease 1 0 event count · % of participants | 36.4% (n=129) vs 13.2% (n=129) placebo @ 26wk*25 mg QDa,e,c,f NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 47 participants as posted show 1 more dose31.3% (n=131) vs 13.2% (n=129) placebo @ 26wk*12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 41 participants as posted | 38.6% (n=334) vs 43.9% (n=321) Oral Semaglutide @ 26wk*100 mge,c,f Yes NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 129 Participants as posted |
| HbA1c Less Than 6 5 responder rate · % of participants | 36.7% (n=90) vs 12.2% (n=90) placebo @ 16wka,c,g NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy show 2 more doses21.4% (n=98) vs 12.2% (n=90) placebo @ 16wk NCT01289119 · Phase 3 · registry result, not featured evidence · combination 30% (n=60) vs 12.2% (n=90) placebo @ 16wk NCT01289119 · Phase 3 · registry result, not featured evidence · combination | 20% (n=95) vs 22.2% (n=9) Metformin @ 54wkc,g NCT01485614 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% event count · % of participants | 44.4% (n=207) vs 18.3% (n=104) placebo @ 26wk*25 mg QDa,e,c,f NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 92 participants as posted show 1 more dose51.6% (n=213) vs 18.3% (n=104) placebo @ 26wk*12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 110 participants as posted | 36.5% (n=334) vs 43.3% (n=321) Oral Semaglutide @ 26wk*100 mge,c,f Yes NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted |
| HbA1c Less Than or Equal to 6.5 event count · % of participants | 17.4% (n=207) vs 3.8% (n=104) placebo @ 26wk*25 mg QDa,e,c,f NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted show 1 more dose19.7% (n=213) vs 3.8% (n=104) placebo @ 26wk*12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 42 participants as posted | 16.2% (n=334) vs 25.2% (n=321) Oral Semaglutide @ 26wk*100 mge,c,f Yes NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 54 Participants as posted |
| HOMA-B absolute change · percentage points | 15.02% (n=404) vs 2.057% (n=399) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metforminc,f,h NCT00432276 · Phase 3 · registry result, not featured evidence · combination | -41.15% (n=36) vs -1860.69% (n=5) Metformin @ 54wkc,f,h NCT01485614 · Phase 3 · registry result, not featured evidence |
| PPG 2h Change mg/dL absolute change · mmol/L | 3.24 vs 3.39 Voglibose mmol/L @ 52wk*25 mg QDa,i,c,f NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 58.3 mg/dL as posted show 7 more doses3.35 vs 2.92 Voglibose mmol/L*25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 60.4 mg/dL as posted 3.47 vs 3.39 Voglibose mmol/L @ 52wk*12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 62.6 mg/dL as posted 3.54 vs 2.92 Voglibose mmol/L*12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 63.8 mg/dL as posted 2.88 vs 3.39 Voglibose mmol/L @ 52wk*50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 51.8 mg/dL as posted 2.92 vs 2.92 Voglibose mmol/L*50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 52.6 mg/dL as posted 3.65 vs 3.39 Voglibose mmol/L @ 52wk*6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65.7 mg/dL as posted 3.61 vs 2.92 Voglibose mmol/L*6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65 mg/dL as posted | -6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*i,c,f NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted |
| Dropout rate | 40.3%25 mg QDj NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results36.6%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.3%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 21.1%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 11% NCT00968708 · Phase 3 14.9% NCT01456130 · Phase 3 · registry result, not featured evidence 44.3%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 46.4%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.8%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 6.1%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 36.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 38.8%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 20.5%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 37.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 17.1%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 0%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 4.5%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 21.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 24.2%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 15.4%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.1%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.3%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 11.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 10.8%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 23.2%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 17.1%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 23.2%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 19.6%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 22.3%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 21.4%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 17.4%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 25.3%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 24.6%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1.9%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 5.7%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 2.6%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 6.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 3.8%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 3.8%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 6.3%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 28.9%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 27.3%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 31.1%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 12.5%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 74.6%100 mgk NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results67.6%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 69.1%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 67.6%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 9% NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0.7%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 10.8%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.7%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.2%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 12.9%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 3% NCT01131182 · Phase 4 · registry result, not featured evidence 20.5%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 10.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence 2.5%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1% NCT01485614 · Phase 3 · registry result, not featured evidence 4.8%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 10.6%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.6% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 4.7%25 mg QDj NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results0.8%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.3%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 5.6% NCT00968708 · Phase 3 6% NCT01456130 · Phase 3 · registry result, not featured evidence 8.4%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 6.8%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 1.1%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 2%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 0%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.2%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 7.4%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 3.6%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 6.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 4.5%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination —25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence —25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 1.6%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 1.5%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.1%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.8%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.8%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 3.7%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3.7%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 4.1%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 3.3%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 3%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 3.8%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 3.8%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 1.2%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 4.4%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 6.8%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 2.3%100 mgk NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results4.2%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence — NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT02318693 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 1.5%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1.5%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence —Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination — NCT01131182 · Phase 4 · registry result, not featured evidence 7.9%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 3.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination — NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence —100 mg NCT04017832 · Phase 3 · registry result, not featured evidence — NCT01485614 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 0.5% NCT03115112 · Phase 3 · registry result, not featured evidence — NCT02791490 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 5.4%25 mg QDj NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results6.1%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.8%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.7%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 33.6% NCT00968708 · Phase 3 9% NCT01456130 · Phase 3 · registry result, not featured evidence 11%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.9%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 2.2%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 0%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 1.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 16.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 16.7%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 0.9%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 3.6%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 1.9%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 8%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 13.6%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 4.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.6%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.3%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.6%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 4.9%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 0.6%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 6.5%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.5%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 3.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2.8%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 5.6%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 5.4%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 2%25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 3.4%25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 10.7%12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 4.9%12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 2.9%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 1.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 8.2%25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 7.9%12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 5.2%50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 2.1%6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.4%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 2.4%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 10%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 7.7%100 mgk NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results10.1%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 80% NCT02556918 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence 0%Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence 0%Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination 0% NCT02256189 · Phase 4 · registry result, not featured evidence 0% NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 7.2%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 3.4% NCT01907854 · Phase 4 · registry result, not featured evidence 2% NCT01686932 · Phase 4 · registry result, not featured evidence 3.6%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.6%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.1%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 3.7%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0% NCT01131182 · Phase 4 · registry result, not featured evidence 3.1%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 4.7%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 0% NCT00686634 · Phase 4 · registry result, not featured evidence 2.7% NCT00729326 · Phase 4 · registry result, not featured evidence 4.2%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 10.5% NCT01485614 · Phase 3 · registry result, not featured evidence 6.5%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 6.7%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.1% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg QDj urinary tract infection 7% (placebo 7.8%) diarrhoea 6.2% (placebo 5.4%) nasopharyngitis 6.2% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results12.5 mg QD arthralgia 6.9% (placebo 2.3%) urinary tract infection 6.1% (placebo 7.8%) headache 5.3% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 25 mg QD nasopharyngitis 7.6% (placebo 7.8%) headache 6.8% (placebo 4.7%) upper respiratory tract infection 4.5% (placebo 9.4%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 12.5 mg QD nasopharyngitis 9% (placebo 7.8%) headache 7.5% (placebo 4.7%) back pain 5.3% (placebo 4.7%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 25 mg headache 18.7% (placebo 10.5%) hyperglycaemia 12% (placebo 11.8%) diarrhoea 9.3% (placebo 9.2%) NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 renal impairment 7.5% (placebo 6.5%) hypertension 7.1% (placebo 7.4%) hypoglycaemia 6.2% (placebo 5.9%) NCT00968708 · Phase 3 nasopharyngitis 35.8% upper respiratory tract inflammation 11.9% arthralgia 7.5% NCT01456130 · Phase 3 · registry result, not featured evidence 25 mg upper respiratory tract infection 10.3% hypertension 7.6% nasopharyngitis 7.6% NCT00856284 · Phase 3 · registry result, not featured evidence · combination 12.5 mg upper respiratory tract infection 9.6% nasopharyngitis 8.9% diarrhoea 6.9% NCT00856284 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 6.5% (placebo 1.1%) upper respiratory tract infection 5.4% (placebo 3.3%) blood triglycerides increased 2.2% (placebo 1.1%) NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy upper respiratory tract infection 3% (placebo 3.3%) blood triglycerides increased 2% (placebo 1.1%) urinary tract infection 2% (placebo 6.5%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 21.3% (placebo 1.1%) urinary tract infection 6.6% (placebo 6.5%) upper respiratory tract infection 3.3% (placebo 3.3%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination 25 mg hypertension 14.5% urinary tract infection 11.7% nasopharyngitis 11.6% NCT00306384 · Phase 3 · registry result, not featured evidence 12.5 mg hypertension 14.8% upper respiratory tract infection 11.6% urinary tract infection 11.1% NCT00306384 · Phase 3 · registry result, not featured evidence 25 mg QD hyperglycaemia 17% (placebo 26.4%) nasopharyngitis 6.3% (placebo 1.9%) headache 5.4% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence 12.5 mg BID hyperglycaemia 11.8% (placebo 26.4%) headache 4.5% (placebo 2.8%) creatinine renal clearance decreased 3.6% (placebo 3.8%) NCT01023581 · Phase 3 · registry result, not featured evidence alogliptin 12.5 mg BID + metformin 1000 mg BID creatinine renal clearance decreased 7.9% (placebo 3.8%) diarrhoea 7% (placebo 2.8%) dyspepsia 7% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination alogliptin 12.5 mg BID + metformin 500 mg BID hyperglycaemia 7.5% (placebo 26.4%) upper respiratory tract infection 7.5% (placebo 2.8%) headache 6.6% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 20% (placebo 4.2%) anaemia 12% (placebo 4.2%) constipation 8% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence 25 mg QD + 30 mg QD hypoglycaemia 13.6% (placebo 0%) nasopharyngitis 13.6% (placebo 4.2%) constipation 9.1% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence · combination Alogliptin 25 mg; Pioglitazone 30 mg; Metformin upper respiratory tract infection 7.2% nasopharyngitis 6.9% hypertension 5.9% NCT00432276 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 7% (placebo 4.7%) upper respiratory tract infection 6.2% (placebo 3.9%) abdominal pain upper 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence 12.5 mg hypertriglyceridaemia 5.5% (placebo 2.3%) hypertension 4.7% (placebo 3.1%) urinary tract infection 4.7% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence 25 mg + 15 mg influenza 6.2% (placebo 2.3%) nasopharyngitis 6.2% (placebo 3.9%) oedema peripheral 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 30 mg nasopharyngitis 6.9% (placebo 3.9%) back pain 6.2% (placebo 3.9%) influenza 6.2% (placebo 2.3%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 45 mg diarrhoea 5.4% (placebo 8.5%) headache 4.6% (placebo 4.7%) oedema peripheral 4.6% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 15 mg hypertension 6.9% (placebo 3.1%) nasopharyngitis 6.2% (placebo 3.9%) dizziness 5.4% (placebo 3.1%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg dizziness 3.8% (placebo 3.1%) nasopharyngitis 3.8% (placebo 3.9%) upper respiratory tract infection 3.8% (placebo 3.9%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 45 mg back pain 9.2% (placebo 3.9%) dizziness 4.6% (placebo 3.1%) headache 4.6% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 6.7% urinary tract infection 3% oedema peripheral 1.2% NCT00395512 · Phase 3 · registry result, not featured evidence 25 mg + 30 mg headache 12.2% back pain 6.1% urinary tract infection 5.5% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg headache 8.6% urinary tract infection 3.7% back pain 1.8% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 7% (placebo 6.2%) influenza 5.5% (placebo 4.1%) oedema peripheral 5.5% (placebo 7.2%) NCT00286494 · Phase 3 · registry result, not featured evidence 12.5 mg QD oedema peripheral 6.1% (placebo 7.2%) upper respiratory tract infection 5.6% (placebo 5.2%) nausea 4.5% (placebo 2.1%) NCT00286494 · Phase 3 · registry result, not featured evidence 25 mg QD diarrhoea 3.4% (placebo 5.8%) nasopharyngitis 3.4% (placebo 5.8%) bronchitis 2.9% (placebo 1.9%) NCT00286442 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 6.6% (placebo 3.8%) nasopharyngitis 5.6% (placebo 5.8%) upper respiratory tract infection 4.7% (placebo 6.7%) NCT00286442 · Phase 3 · registry result, not featured evidence 25 mg QD headache 5.6% (placebo 3%) hypertension 5.6% (placebo 2%) urinary tract infection 5.1% (placebo 3%) NCT00286468 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 4.4% (placebo 3%) diarrhoea 3.9% (placebo 0%) hypertriglyceridaemia 3.9% (placebo 2%) NCT00286468 · Phase 3 · registry result, not featured evidence 25 mg QD and 1-6 mg QD or BID nasopharyngitis 37.5% upper respiratory tract inflammation 10.5% fall 7.9% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 36.6% diabetic retinopathy 6.9% constipation 5.5% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 1-6 mg QD or BID nasopharyngitis 30.7% upper respiratory tract inflammation 6.7% back pain 5.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 31% back pain 6.3% headache 6.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 19.2% upper respiratory tract inflammation 11.5% back pain 3.8% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 19% gastroenteritis 3.8% upper respiratory tract inflammation 1.9% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 25 mg QD and Voglibose 0.2 mg TID nasopharyngitis 28.6% back pain 5.7% arthralgia 4.8% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID nasopharyngitis 35.2% upper respiratory tract inflammation 11.1% back pain 7.4% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 11.5% blood creatine phosphokinase increased 3.5% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 4.5% blood creatine phosphokinase increased 0% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 22.4% eczema 1.3% NCT01263483 · Phase 2/3 · registry result, not featured evidence 25 mg QD + 0.2 mg TID nasopharyngitis 16.5% eczema 0% NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 33% headache 7.2% upper respiratory tract inflammation 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 28.7% bronchitis 5.9% back pain 5% NCT01263496 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 35.1% blood creatine phosphokinase increased 8.2% back pain 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 30.2% upper respiratory tract inflammation 8.3% back pain 7.3% NCT01263496 · Phase 2 · registry result, not featured evidence 25 mg QD nasopharyngitis 12.5% (placebo 6.7%) headache 6.3% (placebo 5.3%) abdominal distension 3.8% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 8.3% (placebo 6.7%) flatulence 4.8% (placebo 2.7%) urticaria 3.6% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 10.1% (placebo 6.7%) blood creatine phosphokinase increased 5.1% (placebo 2.7%) abdominal distension 2.5% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 6.3% (placebo 6.7%) bronchitis 3.8% (placebo 1.3%) flatulence 2.5% (placebo 2.7%) NCT01263470 · Phase 2 · registry result, not featured evidence 25 mg QD headache 8.9% (placebo 7.3%) abdominal pain upper 6.7% (placebo 0%) dizziness 6.7% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 12.5 mg QD rash 9.1% (placebo 2.4%) abdominal pain 4.5% (placebo 0%) arthralgia 4.5% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 100 mg QD nausea 11.4% (placebo 0%) headache 9.1% (placebo 7.3%) urinary tract infection 9.1% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 50 mg QD diarrhoea 7% (placebo 7.3%) headache 7% (placebo 7.3%) urinary tract infection 7% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 6.25 mg QD urinary tract infection 7.1% (placebo 9.8%) abdominal pain upper 4.8% (placebo 0%) dizziness 4.8% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 25 mg rash papular 25% abdominal pain 0% blood creatine phosphokinase increased 0% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg blood creatine phosphokinase increased 14.3% haematocrit decreased 14.3% haemoglobin decreased 14.3% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg headache 18.2% fatigue 9.1% nausea 9.1% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg diarrhoea 20% neutrophil count decreased 20% pyrexia 20% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg abdominal pain 25% gastritis 12.5% headache 12.5% NCT00957268 · Phase 1 · registry result, not featured evidence headache 30% nausea 20% constipation 10% NCT01664624 · Phase 1 · registry result, not featured evidence · combination nausea 50% diarrhoea 40% vomiting 30% NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 100 mgk upper respiratory tract infection 13.1% dizziness 11.5% nasopharyngitis 9.2% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 30 more results100 mg/100 mg upper respiratory tract infection 15.1% dizziness 10.5% nasopharyngitis 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg upper respiratory tract infection 11.4% arthralgia 9.8% blood glucose increased 8.9% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg/200 mg upper respiratory tract infection 16.4% dizziness 12.4% influenza 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg any infections and infestations 6.3% (placebo 3.4%) upper respiratory tract infection 6.3% (placebo 3.4%) any nervous system disorders 5.1% (placebo 3.9%) NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 infection 2% (placebo 2%) headache 1% (placebo 1%) loss of appetite 1% (placebo 0%) NCT02556918 · Phase 4 · registry result, not featured evidence 100 mg headache 1.6% hypertension 1.6% diarrhoea 0% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 15.8% arrhythmic events 5.3% genital infection 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence light-headedness 7.7% (placebo 7.7%) paresthesias 7.7% (placebo 0%) nausea 0% (placebo 7.7%) NCT02639637 · Phase 4 · registry result, not featured evidence light-headedness 0% (placebo 7.7%) nausea 0% (placebo 7.7%) paresthesias 0% (placebo 0%) NCT02639637 · Phase 4 · registry result, not featured evidence · combination rash 0% (placebo 2.8%) NCT01859793 · Phase 4 · registry result, not featured evidence hypoglycemia 0% NCT02312063 · Phase 4 · registry result, not featured evidence urinary tract infection 1.4% wound infection 0% NCT01845831 · Phase 4 · registry result, not featured evidence · combination 50 mg erythema 38.5% hypoglycaemia 7.7% periodontitis 7.7% NCT02318693 · Phase 4 · registry result, not featured evidence diarrhoea 9.3% nausea 7.8% upper respiratory tract infection 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence hypoglycaemia 14% blood glucose decreased 6% NCT01686932 · Phase 4 · registry result, not featured evidence influenza 5.7% nasopharyngitis 4.7% diarrhoea 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination headache 5.7% nasopharyngitis 5.7% influenza 2.6% NCT01519674 · Phase 4 · registry result, not featured evidence · combination diarrhoea 5.3% influenza 5.3% headache 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination hyperglycemia 11.1% pressure ulcer/skin ulcer 11.1% hypoglycemia 3.7% NCT01378117 · Phase 4 · registry result, not featured evidence · combination hypoglycemia 6.9% pneumonia 6.9% urinary tract infection 6.9% NCT01378117 · Phase 4 · registry result, not featured evidence · combination headache 4.9% dizziness 3.9% hyperhidrosis 3.7% NCT01131182 · Phase 4 · registry result, not featured evidence nausea 15.7% vomiting 10.2% nasopharyngitis 8.7% NCT00870194 · Phase 4 · registry result, not featured evidence nausea 10.2% nasopharyngitis 7.8% headache 7% NCT00870194 · Phase 4 · registry result, not featured evidence · combination nausea 37% vomiting 20.5% headache 12.3% NCT00729326 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 7.8% diarrhoea 4.5% nausea 3.9% NCT04017832 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.8% nasopharyngitis 15.8% upper respiratory tract infection 12.6% NCT01485614 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.1% upper respiratory tract infection 14.5% diarrhoea 11.3% NCT01760447 · Phase 3 · registry result, not featured evidence hypoglycaemia 20% upper respiratory tract infection 11.1% abdominal pain 8.9% NCT01760447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13% hypoglycemia 5.2% influenza 5.2% NCT03115112 · Phase 3 · registry result, not featured evidence diarrhoea 7.9% (placebo 4.8%) NCT02791490 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 2/3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- eThe reported result categories differ.
- fTreatment context has not been resolved for both arms.
- gAssessment timepoints differ: 54 weeks versus 16 weeks.
- hAssessment timepoints differ: 54 weeks versus 52 weeks.
- iTrial phases differ: Phase 4 versus Phase 2.
- jPopulation comparability has not been reviewed for 65 of these studies.
- kPopulation comparability has not been reviewed for 33 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alogliptin
show 5 more results
show 7 more results
show 7 more results
show 7 more results
show 9 more results
show 9 more results
show 9 more results
show 10 more results
+ 50 further endpoints in the CSV export.
Sitagliptin
show 3 more results
show 3 more results
show 1 more result
show 2 more results
show 1 more result
show 2 more results
+ 62 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Sitagliptin's landscape